Kaan Kavaklı

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

Guy Young, Alok Srivastava, Kaan Kavaklı et al. · The Lancet · 2023 · 121 citations

Medicine, Pharmacology, Pharmacotherapy +4

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Renchi Yang, L. Rusen, H. Beckmann et al. · Journal of Thrombosis and Haemostasis · 2014 · 88 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

Alok Srivastava, Savita Rangarajan, Kaan Kavaklı et al. · The Lancet Haematology · 2023 · 88 citations

Medicine, Hematology, Pharmacology +5

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment

Nadine G. Andersson, Günter Auerswald, Chris Barnes et al. · British Journal of Haematology · 2017 · 78 citations · Full text

Medicine, Hematology, Pediatrics +9

Prospective Evaluation of Whole Genome MicroRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia

Muhterem Duyu, Burak Durmaz, Cumhur Gündüz et al. · BioMed Research International · 2014 · 57 citations · Full text

Medicine, Molecular Biology, Oncology +15